The anticancer potential of ibuprofen has created a broad interest to explore the clinical benefits of ibuprofen in cancer therapy. However, the current understanding of the molecular mechanisms involved in the anticancer potential of ibuprofen remains limited.
Cancer stemness assays to validate ibuprofen function in vitro and in vivo. Histone modification assays to check the effect of ibuprofen on histone acetylation/methylation, as well as the activity of HDAC and KDM6A/B. Inhibitors’ in vivo assays to evaluate therapeutic effects of various inhibitors’ combination manners.
In our in vitro studies, we report that ibuprofen diminishes cancer cell stemness properties that include reducing the ALDH + subpopulation, side population and sphere formation in three cancer types. In our in vivo studies, we report that ibuprofen decreases tumour growth, metastasis and prolongs survival. In addition, our results showed that ibuprofen inhibits inflammation-related stemness gene expression (especially ICAM3) identified by a high-throughput siRNA platform. In regard to the underlying molecular mechanism of action, we report that ibuprofen reduces HDACs and histone demethylase (KDM6A/B) expression that mediates histone acetylation and methylation, and suppresses gene expression via a COX2-dependent way. In regard to therapeutic strategies, we report that ibuprofen combined HDAC/HDM inhibitors prevents cancer progression in vivo.
The aforementioned findings suggest a molecular model that explains how ibuprofen diminishes cancer cell stemness properties. These may provide novel targets for therapeutic strategies involving ibuprofen in the prevention of cancer progression.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Jones, D. L. & Wagers, A. J. No place like home: anatomy and function of the stem cell niche. Nat. Rev. Mol. Cell Biol. 9, 11–21 (2008).
Prewitz, M. C., Seib, F. P., von Bonin, M., Friedrichs, J., Stissel, A., Niehage, C. et al. Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments. Nat. Methods 10, 788–794 (2013).
Visvader, J. E. & Lindeman, G. J. Cancer stem cells: current status and evolving complexities. Cell. Stem Cell. 10, 717–728 (2012).
van der Zee, M., Sacchetti, A., Cansoy, M., Joosten, R., Teeuwssen, M., Heijmans-Antonissen, C. et al. IL6/JAK1/STAT3 signaling blockade in endometrial cancer affects the ALDHhi/CD126+ stem-like component and reduces tumor burden. Cancer Res. 75, 3608–3622 (2015).
Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T. H., Xiang, R. et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway. Stem Cells 31, 248–258 (2013).
Shen, W., Xie, J., Zhao, S., Du, R., Luo, X., He, H. et al. ICAM3 mediates inflammatory signaling to promote cancer cell stemness. Cancer Lett. 422, 29–43 (2018).
Schack A., Fransgaard T., Klein M. F. & Gogenur I. Perioperative use of nonsteroidal anti-inflammatory drugs decreases the risk of recurrence of cancer after colorectal resection: a cohort study based on prospective data. Ann. Surg Oncol. 26, 3826–3837 (2019).
Kehm, R. D., Hopper, J. L., John, E. M., Phillips, K. A., MacInnis, R. J., Dite, G. S. et al. Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. Breast Cancer Res. 21, 52 (2019).
Pennock, N. D., Martinson, H. A., Guo, Q., Betts, C. B., Jindal, S., Tsujikawa, T. et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J. Immunother. Cancer 6, 98 (2018).
Liu, X., Wang, X., Zhao, W., Wei, L., Zhang, P. & Han, F. A prospective, randomized, double-blind, placebo-controlled trial of acute postoperative pain treatment using opioid analgesics with intravenous ibuprofen after radical cervical cancer surgery. Sci. Rep. 8, 10161 (2018).
Akrami, H., Moradi, B., Borzabadi Farahani, D. & Mehdizadeh, K. Ibuprofen reduces cell proliferation through inhibiting Wnt/beta catenin signaling pathway in gastric cancer stem cells. Cell Biol. Int. 42, 949–958 (2018).
Stabile, L. P., Farooqui, M., Kanterewicz, B., Abberbock, S., Kurland, B. F., Diergaarde, B. et al. Preclinical evidence for combined use of aromatase inhibitors and NSAIDs as preventive agents of tobacco-induced lung cancer. J. Thorac. Oncol. 13, 399–412 (2018).
Ait Ouakrim, D., Dashti, S. G., Chau, R., Buchanan, D. D., Clendenning, M., Rosty, C. et al. Aspirin, ibuprofen, and the risk of colorectal cancer in lynch syndrome. J. Natl Cancer Inst. 107, 9 (2015).
Becker, C., Wilson, J. C., Jick, S. S. & Meier, C. R. Non-steroidal anti-inflammatory drugs and the risk of head and neck cancer: a case-control analysis. Int. J. Cancer 137, 2424–2431 (2015).
Khan, M. N. & Lee, Y. S. Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy. Med. Res. Rev. 31, 161–201 (2011).
Qadri, S. S., Wang, J. H., Redmond, K. C., AF, O. D., Aherne, T. & Redmond, H. P. The role of COX-2 inhibitors in lung cancer. Ann. Thorac. Surg. 74, 1648–1652 (2002).
Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 21, 381–395 (2011).
Zou, C. & Mallampalli, R. K. Regulation of histone modifying enzymes by the ubiquitin-proteasome system. Biochim Biophys. Acta 1843, 694–702 (2014).
Kondo, Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med. J. 50, 455–463 (2009).
Greer, E. L. & Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 13, 343–357 (2012).
Guo, Y., Liu, Y., Zhang, C., Su, Z. Y., Li, W., Huang, M. T. et al. The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice. Carcinogenesis 37, 616–624 (2016).
Son, D. S., Wilson, A. J., Parl, A. K. & Khabele, D. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biol. Ther. 9, 928–935 (2010).
Chen, Z., Li, W., Qiu, F., Huang, Q., Jiang, Z., Ye, J. et al. Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer. Theranostics 8, 4447–4461 (2018).
Zhao, S., Shen, W., Yu, J. & Wang, L. TBX21 predicts prognosis of patients and drives cancer stem cell maintenance via the TBX21-IL-4 pathway in lung adenocarcinoma. Stem Cell Res. Ther. 9, 89 (2018).
Shen, W., Zhang, X., Du, R., Fan, Y., Luo, D., Bao, Y. et al. ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner. Biochim Biophys. Acta 1864, 2566–2578 (2018).
Shen, W., Chang, A., Wang, J., Zhou, W., Gao, R., Li, J. et al. TIFA, an inflammatory signaling adaptor, is tumor suppressive for liver cancer. Oncogenesis 4, e173 (2015).
Shen, W., Du, R., Li, J., Luo, X., Zhao, S., Chang, A. et al. TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways. Signal Transduct. Target Ther. 1, 16013 (2016).
Luo, D. H., Zhang, X. Y., Du, R. L., Gao, W. J., Luo, N., Zhao, S. T. et al. Low dosage of arsenic trioxide (As2O3) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis. J. Biol. Inorg. Chem. 23, 939–947 (2018).
Moon, H. J., Kim, H. B., Lee, S. H., Jeun, S. E., Kang, C. D. & Kim, S. H. Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death. Oncotarget 9, 11303–11321 (2018).
Dandah, O., Najafzadeh, M., Isreb, M., Linforth, R., Tait, C., Baumgartner, A. et al. Aspirin and ibuprofen, in bulk and nanoforms: Effects on DNA damage in peripheral lymphocytes from breast cancer patients and healthy individuals. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 826, 41–46 (2018).
Shi, J., Leng, W., Zhao, L., Xu, C., Wang, J., Chen, X. et al. Nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer: a dose-response meta analysis of prospective cohort studies. Oncotarget 8, 99066–99074 (2017).
Tran, B. N., Nguyen, H. T., Kim, J. O., Yong, C. S. & Nguyen, C. N. Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment. Arch. Pharm. Res. 40, 1420–1432 (2017).
Lima, R. A., Candido, E. B., de Melo, F. P., Piedade, J. B., Vidigal, P. V., Silva, L. M. et al. Gene expression profile of ABC transporters and cytotoxic effect of ibuprofen and acetaminophen in an epithelial ovarian cancer cell line in vitro. Rev. Bras. Ginecol. Obstet. 37, 283–290 (2015).
Simmons, D. L., Botting, R. M. & Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharm. Rev. 56, 387–437 (2004).
Mandal, P., Kundu, B. K., Vyas, K., Sabu, V., Helen, A., Dhankhar, S. S. et al. Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines. Dalton Trans. 47, 517–527 (2018).
Afzal, M., Kazmi, I., Khan, R., Rana, P., Kumar, V., Al-Abbasi, F. A. et al. Thiamine potentiates chemoprotective effects of ibuprofen in DEN induced hepatic cancer via alteration of oxidative stress and inflammatory mechanism. Arch. Biochem. Biophys. 623–624, 58–63 (2017).
Magee, J. A., Piskounova, E. & Morrison, S. J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 21, 283–296 (2012).
Nassar, D. & Blanpain, C. Cancer stem cells: basic concepts and therapeutic implications. Annu. Rev. Pathol. 11, 47–76 (2016).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Ethics approval and consent to participate
All animal experiments were performed in accordance with Nankai University and Jining Medical University Animal Welfare Guidelines.
Consent to publish
The data are available for all study authors. The data sets used and analysed during the current study are available from the corresponding author on reasonable request.
The authors declare no competing interests.
This work was supported by the National Natural Science Foundation of China (No. 81802466 to Wenzhi Shen), Faculty Start-up Funds of Jining Medical University (No. 600640001 to Wenzhi Shen), Shandong Medical Science and Technology Program (No. 2017WS144 to Wenzhi Shen) and Shandong Provincial Natural Science Foundation (No. ZR2019BH003 to Wenzhi Shen).
Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Shen, W., Zhang, X., Du, R. et al. Ibuprofen mediates histone modification to diminish cancer cell stemness properties via a COX2-dependent manner. Br J Cancer 123, 730–741 (2020). https://doi.org/10.1038/s41416-020-0906-7
Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases
Drug Metabolism Reviews (2021)